Combination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis

Peripheral blood samples were obtained at week 0 and week 4 of tocilizumab treatment and global gene expression profiling identified markers of responder status.


Primary Purpose
-
Description of Cohorts
-
Informed Consent Given?
-
Multi-center Study?
-
Organisms
Homo sapiens
Number of subjects
-
Diseases
rheumatoid arthritis
Sample Sources
-
Type of Samples Collected
-
Age Range of Study Participants
-
BMI Range of Study Participants
-